A Phase II Study of ARQ 501 in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

NCT00102700 Phase 2 COMPLETED

The study will document the safety and efficacy of the combination of ARQ 501 and gemcitabine in patients with treatment-naïve, unresectable, metastatic pancreatic adenocarcinoma.

Details

Lead sponsor	ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase	Phase 2
Status	COMPLETED
Enrolment	66
Start date	2005-01
Completion	2007-01

Conditions

• Pancreatic Cancer
• Adenocarcinoma

Interventions

• ARQ 501 in combination with gemcitabine

Primary outcomes

• Document progression free survival after treatment with ARQ 501 and gemcitabine

Countries

United States